BEAM is trading 4.2% up now at $34.87 after a recent multi-day pullback and sector-driven weakness. There are no fresh company-specific headlines, earnings, or FDA updates this morning; the move appears to be a rebound supported by broadly positive U.S. markets and prior bullish sentiment around Beam’s gene-editing pipeline.